menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    US FDA approves Bristol Myers` colorectal cancer therapy

    REUTERS

    ASCO: KRAS upstarts set their sights on NSCLC market

    PHARMAPHORUM

    KRAZATI Improves PFS In Pretreated KRAS G12C Mutant NSCLC

    BUSINESSWIRE

    KRAZATI with Cetuximab Demonstrates Clinically Meaningful Activity

    BUSINESSWIRE

    Zai Lab Partner BMS Announces Trial KRAZATI (adagrasib) Meets Primary Endpoint

    BUSINESSWIRE

    BMS touts KRAS confirmatory trial win after Amgen`s stumble

    FIERCE PHARMA

    BMS Announces Trial Evaluating KRAZATI Meets Primary Endpoint

    BUSINESSWIRE

    FDA Accepts sNDA for KRAZATI in Combination with Cetuximab

    BUSINESSWIRE

    EU body endorses Mirati`s KRAS drug for lung cancer after second look

    PR NEWSWIRE

    Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration

    GLOBENEWSWIRE

    Bazhenova Details Potential Pathways Forward for Targeting KRAS in NSCLC

    ONCLIVE

    Mirati`s lung cancer drug fails to win EU regulator`s backing

    PRESS RELEASE

    Mirati`s KRAS drug Krazati beat estimates in first full quarter

    FIERCE PHARMA

    Mirati announces AdagrasibReceives Breakthrough Therapy Designation from FDA

    PRESS RELEASE

    KRAZATI Available from Onco360 for the Treatment of NSCLC

    BUSINESSWIRE

    QIAGEN receives FDA approval for companion diagnostic to Mirati’s KRAZATI

    BUSINESSWIRE

    U.S. FDA approves Mirati`s lung cancer drug Adagrasib

    PRNEWSWIRE

    Agilent ctDx FIRST Receives FDA Approval as Liquid Biopsy Companion Test

    BUSINESSWIRE

    Mirati to focus KRAS inhibitor, Keytruda combo on low PD-L1 lung cancer

    FIERCEBIOTECH

    Mirati Therapeutics Presents Results Evaluating Adagrasib and Pembrolizumab

    PRESS RELEASE

    Mirati gauging sale interest of Big Pharmas — report

    ENDPTS

    Mirati Therapeutics Sues China’s InventisBio for 99 Million RMB in Trade Secret Theft Case

    NALTAWREVIEW

    Mirati & Aadi Partner to Evaluate the Combination of Adagrasib & Nab-sirolimus

    PRNEWSWIRE

    Mirati Therapeutics Presents Late-Breaking Adagrasib

    PRESS RELEASE

    Mirati KRAS data are `identical` to Amgen`s, researcher, CEO say

    FIERCEBIOTECH

    Mirati cedes to Amgen`s Lumakras on durability in KRAS battle

    FIERCEBIOTECH

    Mirati Therapeutics Submits MAA to EMA for Investigational Adagrasib in NSCLC

    BIOSPACE

    Amgen`s Lumakras posts encouraging results in pancreatic cancer

    FIERCEPHARMA

    FDA Accepts Mirati`s NDA of Adagrasib for NSCLC

    PRESS RELEASE

    Mirati goes where Amgen won`t: KRAS drug has 41% response in GI

    FIERCEBIOTECH

    Mirati and Verastem to evaluate lung cancer combination therapy

    CLINICALTRIALSARENA

    Mirati sees more responses for KRAS drug in Keytruda combo

    ENDPTS

    Mirati KRAS concerns as key adagrasib lead, COO suddenly exit

    FIERCEBIOTECH

    Mirati, Sanofi join forces in lung cancer with a KRAS-SHP2 combo

    FIERCEBIOTECH

    Biogen, Mirati, mRNA players on Merck`s M&A shortlist: FT

    FIERCEPHARMA

    David Meek takes over at Mirati with lead KRAS drug racing to an approval

    ENDPTS

    Adagrasib, Cetuximab Combo Shows Promise in Heavily Pretreated Patients

    CANCERNETWORK

    Mirati Presents +ve Data with Adagrasib in KRAS G12C-Mutated Colorectal Cancer

    PRNEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.